Publications in collaboration with researchers from Policlinico S.Orsola-Malpighi (76)

2024

  1. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810

  2. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  3. Corrigendum to “European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO” [Eur J Surg Oncol 50 (1) (January 2024) 107292] (European Journal of Surgical Oncology (2024) 50(1), (S0748798323009307), (10.1016/j.ejso.2023.107292))

    European Journal of Surgical Oncology

  4. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  5. European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO

    European Journal of Surgical Oncology, Vol. 50, Núm. 1

  6. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

    CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

  7. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

  8. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  9. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  10. Is prolonged operative time associated with postoperative complications in liver surgery? An international multicentre cohort study of 5424 patients

    Surgical Endoscopy

  11. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

  12. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  13. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome

    JHEP Reports, Vol. 6, Núm. 7

  14. Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients

    Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117

  15. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network

    European Journal of Cancer, Vol. 196

  16. Trends in the characteristics and perioperative outcomes of patients undergoing laparoscopic and open resections for benign liver lesions: An international multicenter retrospective cohort study of 845 patients

    HPB, Vol. 26, Núm. 2, pp. 188-202

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

  2. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

    Ultrasound in Obstetrics and Gynecology, Vol. 61, Núm. 2, pp. 231-242

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

    The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381